EVALUATING EOSINOPHILS AS PHARMACODYNAMIC BIOMARKERS OF MEPOLIZUMAB AND RESLIZUMAB FOR PATIENTS WITH EOSINOPHILIC ASTHMA.

被引：0
|
作者：
Gershuny, V. [1 ]
Florian, J. [1 ]
Wang, Y. [1 ]
Strauss, D. [1 ]
机构：
[1] US FDA, Silver Spring, MD USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2021年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PIV-003
引用
收藏
页码：S62 / S62
页数：1
相关论文
共 50 条
  • [41] Mepolizumab and benralizumab in patients with severe asthma and a history of eosinophilic granulomatosis with polyangiitis
    Desaintjean, Charlene
    Ahmad, Kais
    Traclet, Julie
    Gerfaud-Valentin, Mathieu
    Durel, Cecile-Audrey
    Glerant, Jean-Charles
    Hot, Arnaud
    Lestelle, Francois
    Mainbourg, Sabine
    Nasser, Mouhamad
    Seve, Pascal
    Turquier, Segolene
    Devouassoux, Gilles
    Cottin, Vincent
    FRONTIERS IN MEDICINE, 2024, 11
  • [42] EFFICACY OF BENRALIZUMAB AND MEPOLIZUMAB ON ASTHMA OUTCOMES IN PATIENTS WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
    Wechsler, M.
    Bourdin, A.
    Chanez, P.
    Jackson, D.
    Siddiqui, S.
    Specks, U.
    Baudy, P.
    Necander, S.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2024, 133 (06) : S49 - S50
  • [43] Prevalence of adrenal insufficiency in patients started on Mepolizumab for severe eosinophilic asthma
    Tavernier, Gael
    Elsey, Lynn
    Bhola, Nusrat
    Holmes, Leanne
    Allen, David
    Niven, Robert
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [44] Effect of Mepolizumab in Severe Eosinophilic Asthma Patients with History of Omalizumab Treatment
    Albers, Frank C.
    Bourdin, Arnaud
    Price, Robert
    Yancey, Steven W.
    Prazma, Charlene M.
    Ortega, Hector
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 135 (02) : AB383 - AB383
  • [45] Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes
    Prazma, Charlene M.
    Idzko, Marco
    Douglass, Jo Anne
    Bourdin, Arnaud
    Mallett, Stephen
    Albers, Frank C.
    Yancey, Steven W.
    JOURNAL OF ASTHMA AND ALLERGY, 2021, 14 : 675 - 683
  • [46] THE VALUE OF ORAL PREDNISOLONE IN PATIENTS WITH SEVERE EOSINOPHILIC ASTHMA ON MEPOLIZUMAB TREATMENT
    Yang, J. F.
    Busby, J.
    Heaney, L. G.
    Brightling, C. E.
    Pavord, I. D.
    Borg, K.
    McDowell, P. J.
    Diver, S.
    Shrimanker, R.
    Smith, S. J.
    Shepherd, M.
    Lee, W. N.
    Chaudhuri, R.
    THORAX, 2021, 76 : A141 - A141
  • [47] Effect Of Mepolizumab In Severe Eosinophilic Asthma Patients Eligible For Omalizumab Treatment
    Albers, F. C.
    Price, R.
    Yancey, S.
    Bradford, E.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [48] Mepolizumab in Pediatric Patients with Severe Eosinophilic Asthma: A Single Center Experience
    Rotolo, S. M.
    Hegde, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [49] Efficacy of Reslizumab in Patients with Poorly Controlled Eosinophilic Asthma: Subgroup Analysis of Patients with Nasal Polyps
    Mathur, S.
    Castro, M.
    Hargreave, F.
    Xie, F.
    Wilkins, H. J.
    Henkel, T.
    Nair, P.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 127 (02) : AB84 - AB84
  • [50] Real-World Clinical Outcomes of Asthma patients switched from Reslizumab to either Mepolizumab or Benralizumab
    Walsh, Laura J.
    Casey, Deborah
    Vairamani, Punitha
    Arnott, Fiona
    Plant, Barry J.
    Murphy, Desmond M.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2022, 191 : S138 - S138
12345